TY - JOUR
T1 - Enfortumab Vedotin-Related Skin Toxicities
T2 - Insights From Clinical and Histopathological Analysis
AU - Kuma, Yuki
AU - Kido-Nakahara, Makiko
AU - Kuba-Fuyuno, Yoko
AU - Matsumoto, Takashi
AU - Oda, Yoshinao
AU - Eto, Masatoshi
AU - Nakahara, Takeshi
N1 - Publisher Copyright:
© 2025 The Author(s). The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
PY - 2025/10
Y1 - 2025/10
N2 - Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities. This study examined the possible contribution of prior immune checkpoint inhibitor (ICI) therapy and higher EV doses to EV-related skin toxicity (EVST) development. Histopathological findings suggested both direct keratinocyte damage and immune-mediated mechanisms. These insights may improve clinical management of EVST.
AB - Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities. This study examined the possible contribution of prior immune checkpoint inhibitor (ICI) therapy and higher EV doses to EV-related skin toxicity (EVST) development. Histopathological findings suggested both direct keratinocyte damage and immune-mediated mechanisms. These insights may improve clinical management of EVST.
KW - Enfortumab vedotin
KW - immune checkpoint inhibitors
KW - skin toxicity
KW - urothelial carcinomaantibody-drug conjugate
UR - https://www.scopus.com/pages/publications/105013116246
UR - https://www.scopus.com/pages/publications/105013116246#tab=citedBy
U2 - 10.1111/1346-8138.17901
DO - 10.1111/1346-8138.17901
M3 - Article
C2 - 41100408
AN - SCOPUS:105013116246
SN - 0385-2407
VL - 52
SP - 1584
EP - 1588
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 10
ER -